CA2882248A1 - Exosome-based therapeutics against neurodegenerative disorders - Google Patents

Exosome-based therapeutics against neurodegenerative disorders Download PDF

Info

Publication number
CA2882248A1
CA2882248A1 CA2882248A CA2882248A CA2882248A1 CA 2882248 A1 CA2882248 A1 CA 2882248A1 CA 2882248 A CA2882248 A CA 2882248A CA 2882248 A CA2882248 A CA 2882248A CA 2882248 A1 CA2882248 A1 CA 2882248A1
Authority
CA
Canada
Prior art keywords
cells
exosomes
mir
patient
isolated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2882248A
Other languages
English (en)
French (fr)
Inventor
Kae M. Pusic
Yelena Y. Grinberg
Richard P. Kraig
Aya D. Pusic
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Chicago
Original Assignee
University of Chicago
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Chicago filed Critical University of Chicago
Publication of CA2882248A1 publication Critical patent/CA2882248A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/35—Fat tissue; Adipocytes; Stromal cells; Connective tissues
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5063—Compounds of unknown constitution, e.g. material from plants or animals
    • A61K9/5068—Cell membranes or bacterial membranes enclosing drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/31—Combination therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Botany (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
CA2882248A 2012-08-15 2013-08-15 Exosome-based therapeutics against neurodegenerative disorders Abandoned CA2882248A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261683596P 2012-08-15 2012-08-15
US61/683,596 2012-08-15
PCT/US2013/055187 WO2014028763A1 (en) 2012-08-15 2013-08-15 Exosome-based therapeutics against neurodegenerative disorders

Publications (1)

Publication Number Publication Date
CA2882248A1 true CA2882248A1 (en) 2014-02-20

Family

ID=50101510

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2882248A Abandoned CA2882248A1 (en) 2012-08-15 2013-08-15 Exosome-based therapeutics against neurodegenerative disorders

Country Status (6)

Country Link
US (2) US10231997B2 (OSRAM)
EP (1) EP2885414B1 (OSRAM)
JP (1) JP2015524849A (OSRAM)
AU (1) AU2013302526B2 (OSRAM)
CA (1) CA2882248A1 (OSRAM)
WO (1) WO2014028763A1 (OSRAM)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8822663B2 (en) 2010-08-06 2014-09-02 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
CA2821992A1 (en) 2010-10-01 2012-04-05 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
DE12722942T1 (de) 2011-03-31 2021-09-30 Modernatx, Inc. Freisetzung und formulierung von manipulierten nukleinsäuren
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
HRP20220250T1 (hr) 2011-10-03 2022-04-29 Modernatx, Inc. Modificirani nukleozidi, nukleotidi i nukleinske kiseline, te njihove uporabe
SI2791160T1 (sl) 2011-12-16 2022-07-29 Modernatx, Inc. Sestave modificirane MRNA
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US10501512B2 (en) 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides
AU2013243952A1 (en) 2012-04-02 2014-10-30 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
WO2014028763A1 (en) 2012-08-15 2014-02-20 The University Of Chicago Exosome-based therapeutics against neurodegenerative disorders
SMT202200337T1 (it) 2012-11-26 2022-09-14 Modernatx Inc Rna modificato al livello del terminale
EP2971010B1 (en) 2013-03-14 2020-06-10 ModernaTX, Inc. Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
US10323076B2 (en) 2013-10-03 2019-06-18 Modernatx, Inc. Polynucleotides encoding low density lipoprotein receptor
JP6711754B2 (ja) * 2013-10-24 2020-06-17 ナノソミックス・インコーポレイテッドＮａｎｏＳｏｍｉＸ， Ｉｎｃ． アルツハイマー病および他の神経変性障害のためのバイオマーカーおよび診断方法
SG10201912038TA (en) 2014-04-23 2020-02-27 Modernatx Inc Nucleic acid vaccines
AU2015264519B2 (en) * 2014-05-18 2021-01-28 Children's Medical Center Corporation Methods and compositions relating to exosomes
EP3146346A4 (en) * 2014-05-23 2018-03-21 Georgetown University Exosome and lipid biomarkers for memory loss
CN107427592A (zh) 2015-01-05 2017-12-01 株式会社露太利温 使用luterion抑制癌细胞中端粒酶的方法
CA2998810A1 (en) 2015-09-17 2017-03-23 Modernatx, Inc. Compounds and compositions for intracellular delivery of therapeutic agents
IL259470B (en) * 2015-11-18 2022-08-01 Univ Georgia Extracellular vesicles of nerve cells
EP3377043A4 (en) 2015-11-20 2019-06-26 The Regents of The University of California DEVICABLE NANOSCAL CARRIER (DNVS) FOR ADMINISTRATION THROUGH THE BLOOD-BRAIN-BARRIER, MICE AND SKIN
SMT202200252T1 (it) 2015-12-22 2022-07-21 Modernatx Inc Composti e composizioni per il rilascio intracellulare di agenti
WO2017124000A1 (en) 2016-01-14 2017-07-20 The Regents Of The University Of California 3d-exoquant method for the analysis of surface molecules and quantification of tissue-specific exosomes in biological fluids
CN118806792A (zh) 2016-03-02 2024-10-22 高等教育联邦系统-匹兹堡大学 结合基质的纳米囊泡及其用途
WO2017152035A1 (en) * 2016-03-03 2017-09-08 Henry Ford Health System 3-d collagen scaffold-generated exosomes and uses thereof
US11357800B2 (en) 2016-08-16 2022-06-14 Henry Ford Health System Compositions for the treatment of neuropathic pain and sensitization of tumors to chemotherapies
WO2018039119A1 (en) * 2016-08-22 2018-03-01 Codiak Biosciences, Inc. Methods of suppressing delivery of exosomes to liver and spleen
CN110049771A (zh) 2016-10-13 2019-07-23 Vbc控股有限责任公司 癌症干细胞的外泌体
CN110402146A (zh) 2016-11-03 2019-11-01 埃克森蒂姆生物技术公司 间充质干细胞群、其产物及其用途
US11583504B2 (en) 2016-11-08 2023-02-21 Modernatx, Inc. Stabilized formulations of lipid nanoparticles
ES2912270T3 (es) * 2016-11-23 2022-05-25 Mayo Found Medical Education & Res Transporte de productos biológicos por medio de partículas
WO2018132728A1 (en) * 2017-01-12 2018-07-19 Duke University Compositions and methods for the treatment of demyelinating conditions
AU2018234828A1 (en) 2017-03-15 2019-09-19 Modernatx, Inc. Lipid nanoparticle formulation
EP3596041B1 (en) 2017-03-15 2022-11-02 ModernaTX, Inc. Compound and compositions for intracellular delivery of therapeutic agents
AU2018234814B2 (en) 2017-03-15 2022-06-30 Modernatx, Inc. Crystal forms of amino lipids
WO2018208971A1 (en) * 2017-05-10 2018-11-15 University Of Louisville Research Foundation, Inc. Compositions comprising engineered embryonic stem cell-derived exosomes and method of use therefor
WO2018232120A1 (en) 2017-06-14 2018-12-20 Modernatx, Inc. Compounds and compositions for intracellular delivery of agents
WO2018232357A1 (en) 2017-06-15 2018-12-20 Modernatx, Inc. Rna formulations
US11744801B2 (en) 2017-08-31 2023-09-05 Modernatx, Inc. Methods of making lipid nanoparticles
CN108103026B (zh) * 2017-12-05 2020-12-22 四川省肿瘤医院 用于肿瘤免疫治疗的γδ-T细胞外泌体及其制备方法
CN107988153B (zh) * 2017-12-15 2021-05-18 英科博雅生命科技有限公司 人脐带血间充质干细胞源分离外泌体的方法和使用的试剂
WO2019136268A1 (en) * 2018-01-05 2019-07-11 Mayo Foundation For Medical Education And Research Modulation of extracellular vesicles with electrical stimulation
US11278575B2 (en) 2018-07-12 2022-03-22 Duke University Compositions and methods for the treatment of demyelinating conditions
WO2020061367A1 (en) 2018-09-19 2020-03-26 Modernatx, Inc. Compounds and compositions for intracellular delivery of therapeutic agents
WO2020061457A1 (en) 2018-09-20 2020-03-26 Modernatx, Inc. Preparation of lipid nanoparticles and methods of administration thereof
EP3860566A4 (en) * 2018-10-04 2022-06-29 Synaptec Network, Inc. Systems and methods for delivering exosomes through the blood-brain barrier
EP3920950A1 (en) 2019-02-08 2021-12-15 CureVac AG Coding rna administered into the suprachoroidal space in the treatment of ophtalmic diseases
JP2022534786A (ja) * 2019-06-04 2022-08-03 トーマス・ジェファーソン・ユニバーシティ 多発性硬化症療法のためのオリゴデンドロサイト由来細胞外小胞
JP7372518B2 (ja) * 2019-06-27 2023-11-01 国立大学法人山口大学 骨髄由来間葉系幹細胞の培養方法
KR20220041131A (ko) * 2019-07-26 2022-03-31 메이오 파운데이션 포 메디칼 에쥬케이션 앤드 리써치 항산화제 및 항바이러스 조성물 및 방법
CN111117964B (zh) * 2019-07-30 2020-12-01 段海峰 一种肿瘤来源外泌体及其制备方法和用途
TR201911667A2 (tr) * 2019-08-01 2021-02-22 Univ Yeditepe Hücrelerde oluşan protein birikintilerinden kaynaklanan hastalıkların tedavisi için kullanılan bitki eksozomları.
US11066355B2 (en) 2019-09-19 2021-07-20 Modernatx, Inc. Branched tail lipid compounds and compositions for intracellular delivery of therapeutic agents
KR20220131513A (ko) * 2019-10-16 2022-09-28 더 존스 홉킨스 유니버시티 신경병 질환의 치료를 위한 세포외 소낭 기반 제제 및 방법
CN112972702A (zh) * 2019-12-17 2021-06-18 南京大学 用于治疗耐药菌感染的外泌体制剂
JP2023509423A (ja) * 2019-12-31 2023-03-08 チェイス セラピューティクス コーポレイション 神経変性状態のためのバイオマーカーとしてのキナーゼ
JP7562682B2 (ja) * 2020-01-27 2024-10-07 マントラ バイオ，インコーポレイテッド キメラ小胞局在化部分を含む非天然発生の小胞、その産生方法、およびその使用
US20240415780A1 (en) * 2020-03-21 2024-12-19 Florica Therapeutics, Inc. Neuronal diencephalon stem cells and exosomes thereof for the treatment and prevention of diseases
CN111876388A (zh) * 2020-07-24 2020-11-03 赛瑞诚(苏州)生物科技有限公司 一种骨和骨组织靶向外泌体及其制备方法和应用
WO2022023559A1 (en) 2020-07-31 2022-02-03 Curevac Ag Nucleic acid encoded antibody mixtures
WO2022204045A1 (en) * 2021-03-22 2022-09-29 Spiritus Therapeutics, Inc. Diagnostic and therapeutic uses of purified potent exosomes containing disease-based and therapy based signature cargo
WO2023283218A2 (en) * 2021-07-07 2023-01-12 University Of Florida Research Foundation, Incorporated Light-induced cellular production of immune functional extracellular vesicles
CN115006427A (zh) * 2022-05-31 2022-09-06 尧舜泽生物医药(南京)有限公司 骨髓间充质干细胞外泌体在治疗帕金森病中的应用
CN120712096A (zh) * 2022-11-23 2025-09-26 ExoMed私人有限公司 使用源自幼小哺乳动物的细胞外囊泡预防或治疗年龄相关病状的方法
WO2024186630A1 (en) * 2023-03-03 2024-09-12 Henry Ford Health System Use of extracellular vesicles for the treatment of cancer
WO2024230934A1 (en) 2023-05-11 2024-11-14 CureVac SE Therapeutic nucleic acid for the treatment of ophthalmic diseases

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5888773A (en) 1994-08-17 1999-03-30 The United States Of America As Represented By The Department Of Health And Human Services Method of producing single-chain Fv molecules
FR2766205B1 (fr) 1997-07-16 2002-08-30 Inst Nat Sante Rech Med Nouveau procede de sensibilisation de cellules presentatrices d'antigene et nouveaux moyens pour la mise en oeuvre du procede
FR2788780B1 (fr) 1999-01-27 2001-03-30 Ap Cells Inc Procede de preparation de vesicules membranaires
US20040241176A1 (en) 2000-04-27 2004-12-02 Ap Cells. Inc. Method of producing membrane vesicles
US7689196B2 (en) 2002-06-26 2010-03-30 Qualcomm Incorporated Timer-based sleep for terminals in wireless communication systems
AU2005206388A1 (en) * 2004-01-27 2005-08-04 Compugen Ltd. Methods and systems for annotating biomolecular sequences
IL179285A (en) * 2004-05-14 2011-04-28 Rosetta Genomics Ltd Micrornas and uses thereof
EP2613149B1 (en) * 2007-07-25 2014-09-17 University Of Louisville Research Foundation, Inc. Exosome-associated microRNA as a diagnostic marker
CN101861391A (zh) * 2007-08-10 2010-10-13 韦恩州立大学 通过翻译调控基因表达系统检测和调节细胞死亡的组合物和方法
PL2254586T3 (pl) * 2008-02-22 2015-09-30 Agency For Science Tech And Research Astarstar Cząstki mezenchymalnych komórek macierzystych
BRPI0921043A2 (pt) * 2008-11-12 2018-08-07 Caris Life Sciences Luxembourg Holdings métodos e sistemas para usar exossomas para determinar fenótipos
EP2734634B1 (en) 2011-07-22 2019-08-21 The University of Chicago Igf-1 for use in the treatment of migraine
WO2014028763A1 (en) 2012-08-15 2014-02-20 The University Of Chicago Exosome-based therapeutics against neurodegenerative disorders

Also Published As

Publication number Publication date
EP2885414A4 (en) 2016-01-06
WO2014028763A1 (en) 2014-02-20
AU2013302526B2 (en) 2018-03-22
US11369634B2 (en) 2022-06-28
US20190160097A1 (en) 2019-05-30
AU2013302526A1 (en) 2015-04-02
US10231997B2 (en) 2019-03-19
US20150216899A1 (en) 2015-08-06
JP2015524849A (ja) 2015-08-27
EP2885414A1 (en) 2015-06-24
EP2885414B1 (en) 2020-09-23

Similar Documents

Publication Publication Date Title
US11369634B2 (en) Exosome-based therapeutics against neurodegenerative disorders
JP7486836B2 (ja) テロメア伸長に関する化合物、組成物、方法及びキット
Wang et al. Mesenchymal stem cell-derived exosomes reduce A1 astrocytes via downregulation of phosphorylated NFκB P65 subunit in spinal cord injury
Zhang et al. Human umbilical cord mesenchymal stem cell-derived exosomal miR-146a-5p reduces microglial-mediated neuroinflammation via suppression of the IRAK1/TRAF6 signaling pathway after ischemic stroke
Jahangard et al. Therapeutic effects of transplanted exosomes containing miR-29b to a rat model of Alzheimer’s disease
Esteves et al. MicroRNA-124-3p-enriched small extracellular vesicles as a therapeutic approach for Parkinson’s disease
Li et al. Exosomes derived from miR-133b-modified mesenchymal stem cells promote recovery after spinal cord injury
WO2018029656A2 (en) Methods for making and using therapeutic exosomes
Ma et al. Insulin-like growth factor-1 enhances neuroprotective effects of neural stem cell exosomes after spinal cord injury via an miR-219a-2-3p/YY1 mechanism
Orefice et al. Purposing plant-derived exosomes-like nanovesicles for drug delivery: patents and literature review
Pusic et al. Youth and environmental enrichment generate serum exosomes containing miR‐219 that promote CNS myelination
US8962583B2 (en) Treatment of inflammatory diseases using miR-124
JP2022524391A (ja) 合成腫瘍溶解性ｌｎｐレプリコンｒｎａおよびがん免疫治療のための使用
KR101835018B1 (ko) 엑소좀 또는 엑소좀 유래 리보핵산을 포함하는 간섬유증 예방 또는 치료용 조성물
EP3102679A2 (en) Micro-rnas and compositions comprising same for the treatment and diagnosis of serotonin-, adrenalin-, noradrenalin-, glutamate-, and corticotropin-releasing hormone- associated medical conditions
CN121038801A (zh) 来自微藻的细胞外囊泡、它们在鼻内施用时的生物分布及其用途
Wan et al. Engineered extracellular vesicles efficiently deliver CRISPR-Cas9 ribonucleoprotein (RNP) to inhibit herpes simplex virus1 infection in vitro and in vivo
Yasuzaki et al. Localization of exogenous DNA to mitochondria in skeletal muscle following hydrodynamic limb vein injection
Jiang et al. Circular RNA-based therapy provides sustained and robust neuroprotection for retinal ganglion cells
Yang et al. Engineered Exosome‐Based Senolytic Therapy Alleviates Stroke by Targeting p21+ CD86+ Microglia
Liang et al. Small extracellular vesicles from hypoxia-preconditioned bone marrow mesenchymal stem cells attenuate spinal cord injury via miR-146a-5p-mediated regulation of macrophage polarization
Xu et al. Oligodendrocyte progenitor cell-specific delivery of lipid nanoparticles loaded with Olig2 synthetically modified messenger RNA for ischemic stroke therapy
Saleh et al. Therapeutic gene delivery by mesenchymal stem cell for brain ischemia damage: Focus on molecular mechanisms in ischemic stroke
Chinnici et al. Small extracellular vesicles from human fetal dermal cells and their microRNA cargo: KEGG signaling pathways associated with angiogenesis and wound healing
Li et al. IL-4-primed human umbilical cord mesenchymal stem cells-derived extracellular vesicles facilitate recovery in spinal cord injury via the miR-21-5p/PDCD4-mediated shifting of macrophage M1/M2 polarization

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20180803

FZDE Discontinued

Effective date: 20210210